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Sununary The effect of anastrozole ('Arimidex', ZD1033), a new, selective, non-steroidal aromatase inhibitor
on in vivo aromatisation and plasma oestrogen levels was evaluated in post-menopausal women with breast
cancer. Twelve patients progressing after treatment with tamoxifen were randomised to receive anastrozole
1 mg or 10 mg once daily for a 28 day period in a double-blinded crossover design. In vivo aromatisation and
plasma oestrogen levels were determined before commencing treatment and at the end of each 4-week period.
Treatment with anastrozole 1 and 10 mg reduced the percentage aromatisation from 2.25% to 0.074% and
0.043% (mean suppression of 96.7% and 98.1% from baseline) and suppressed plasma levels of oestrone,
oestradiol and oestrone sulphate by >86.5%, >83.5% and >93.5% respectively, irrespective of dose.
Notably, several patients had their oestrone and oestradiol values suppressed beneath the sensitivity limit of the
assays. In conclusion, anastrozole was found to be highly effective in inhibiting in vivo aromatisation with no
difference in efficacy between the two drug doses. Contrary to previous studies on other aromatase inhibitors,
this study revealed an internal consistency between the percentage aromatase inhibition and suppression of
plasma oestrone sulphate.
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Breast cancer is the most common malignancy among women
in the western hemisphere. Many of these patients develop
metastatic disease, for which no cure is currently available.
Because endocrine treatment causes fewer side-effects than
chemotherapy, such therapy is first-line treatment in patients
with metastatic disease and hormone receptor-positive
tumours. While the anti-oestrogen tamoxifen is first choice
of therapy in post-menopausal patients with metastatic breast
cancer. increasing use of tamoxifen as adjuvant therapy
focuses on the need for alternative endocrine treatment
options on relapse in breast cancer patients.
While ovarian oestrogen synthesis ceases at the meno-
pause, oestrogens are synthesised in peripheral tissue from
circulating androgens by the process called aromatisation
(Grodin et al., 1973). The main pathway is conversion of
androstenedione (A) into oestrone (El), with a minor
contribution from conversion of testosterone into oestradiol
(E2) (L0nning et al., 1990).
Aromatase inhibitors are drugs that inhibit the peripheral
conversion of androgens to oestrogens (Santen et al., 1982a),
thereby suppressing plasma oestrogen levels in post-
menopausal women. The first-generation aromatase inhibi-
tor, aminoglutethimide, was implemented in breast cancer
treatment more than 20 years ago (Cash et al., 1967). While
the drug is effective in hormone-sensitive breast cancer, lack
of specificity (inhibition of adrenal steroid-synthesising
enzymes) and side-effects (such as skin rash and lethargy)
provoked the development of new aromatase inhibitors
(Coombes et al., 1984; Evans et al., 1992; Johnston et al.,
1994; Lipton et al., 1995; Santen et al., 1989).
Anastrozole (Arimidex; 2,2'[5-(1H-1,2,4-triazol-1-ylmethyl)
-1,3-phenylene]bis-(2-methylpropiononitrile, Figure 1) is a
new, potent and selective aromatase inhibitor belonging to
the triazole class. Pilot studies in post-menopausal women
have shown the drug to suppress plasma E2 by >80%
(Plourde et al., 1994), and preclinical studies as well as
observations in women suggest the drug to be highly specific
with no influence on adrenal steroid synthesis (Plourde et al.,
1995).
A major problem in evaluating the biochemical efficacy of
aromatase inhibitors has been the lack of internal consistency
between the percentage aromatase inhibition and degree of
plasma oestrogen suppression. While aminoglutethimide
(MacNeill et al., 1992) as well as the second-generation
aromatase inhibitor formestane (Jones et al., 1992) and the
third-generation inhibitor fadrozole (L0nning et al., 1991)
have all been found to inhibit the conversion of A to E1 in
vivo by 85-92%, the same drugs have been reported to
suppress plasma oestrogen levels by only 50-70%
(Vermeulen et al., 1983; Dowsett et al., 1989, 1990).
Accordingly, a major long-standing controversy has been
whether this discrepancy could be caused by alternative
oestrogen sources or could simply reflect methodological
problems.
The primary aim of this study was to evaluate the effects
of two different doses of anastrozole (1 and 10 mg) on in vivo
aromatase inhibition and plasma oestrogen suppression in
post-menopausal breast cancer patients. A secondary aim was
to compare the degree of aromatase inhibition with the
degree of plasma oestrogen suppression by applying recently
developed, highly sensitive methodology for plasma oestrone
sulphate EIS measurement in particular (L0nning and Ekse,
1995).
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Patients and methods
Patients
Twelve post-menopausal women with a diagnosis of
advanced or recurrent breast cancer progressing afterAromatase inhibition with anastrozole
J Geisler et al
previous tamoxifen treatment were enrolled in the study. The
protocol was approved by the regional ethics committee at
the University of Bergen. All patients gave their written
informed consent. The mean age of the participating patients
was 65 years and the mean weight was 67 kg.
Post-menopausal status was defined as age >50 years and
no menstruation during the past 5 years or amenorrhoea for
less than 5 years with follicle-stimulating hormone (FSH)
levels in the post-menopausal range. Women with a drug-
induced menopausal status (e.g. LHRH treatment) and those
who had received treatment with an aromatase inhibitor
within the previous 3 months were not eligible for the study.
All patients included had a WHO performance score of
0-2 at entrance. Patients presenting with life-threatening
visceral disease, an estimated survival of less than 3 months
or a history of a systemic malignancy other than breast
cancer were not eligible.
Of 12 patients that were entered into the study, two (nos. 1
and 2) were protocol deviators and lost for evaluation of in
vivo aromatase activity because of administration of an
incorrect isotope. One of these patients (no. 1) withdrew from
the study having completed the first period of the crossover
phase owing to disease progression and thus was lost for
evaluation of the alterations in plasma sex hormones.
Treatment
Each patient was randomised to receive either 1 mg or 10 mg
anastrozole p.o. once daily for 28 days (period I) and then
crossed over to receive the alternative dose for another 28
days (period II). The study medication was administered
between 08.00 and 10.00 hours. The clinical investigators as
well as the biochemists were blinded to the treatment code.
After the crossover period all patients received anastrozole
10 mg o.d. until evidence of disease progression.
Reagents
[6,7-3H]A (34 Ci mmol-') and E2-6-carboxymethyloxime-
[2-1251]iodo-histamine (2000 Ci mmol-') were obtained from
Amersham, while [4-14C] EB (50-60 mCi mmol-'), [6,7-3H]-
EIS (60 Ci mmol-1) and [2,4,6,7- 3H]E, (85-105 Ci mmol-')
were obtained from DuPont NEN. Solvents were obtained
from BDH Dagenham and were of analytical or HPLC
grade. DEAE-Sephadex was obtained from Pharmacia,
Amberlite and glucuronidase (C 8885) from Sigma.
Measurement of whole body aromatisation
Aromatisation of A to EB in vivo can be measured by
administration of a steady-state infusion or a bolus injection
of A and E1 labelled with different isotopes followed by
determination of the isotope ratio in plasma or urinary
oestrogens respectively. We have developed a high-perfor-
mance liquid chromatography (HPLC) technique to improve
the specificity and sensitivity ofmeasuring the isotope ratio in
urinary oestrogen metabolites (Jacobs et al., 1991). A recent
formal assessment of sensitivity indicated that inhibition of
up to 99.1% was detectable (Dowsett et al., 1995). In the
present study, each patient had in vivo aromatisation
determined before commencing treatment and at the end of
period I and II by use of this urinary HPLC technique. The
injections were administered on day -3, 25 and 53. On each
occasion, the patient received a bolus injection of 500 ,uCi
[3H]A and 5 MCi ['4C]EI dissolved in 50 ml saline containing
8% ethanol (w/w). Aliquots of the isotopes in the injection
mixture were taken for calculation of the ratio of 3H:'4C.
Urine was collected for a period of 96 h, pooled and kept
frozen (-20°C) until time of processing.
Urine analysis
A detailed description of the analytical method and its
reproducibility has been given previously (Jacobs et al.,
1991) with slight modifications (Dowsett et al., 1995). In
brief, the pooled urine samples were thawed and about two-
thirds of the total sample used for analysis. Urinary steroid
glucuronides were concentrated on an Amberlite XAD-2
column using water and methanol as mobile phase followed by
Sep-pak C18 cartridges and a DEAE Sephadex A-25 column
eluted by a salt gradient. The glucuronides were hydrolysed
with 1 ml (144 000 units) fl-glucuronidase (Sigma, C-8885)
dissolved in 20 ml 0.1 M acetic acid buffer, pH 4, and
incubated at 37°C for 48 h. The unconjugated steroids were
separated from the water phase by ether extraction. The ether
extract was subsequently washed with sodium bicarbonate
(8%). The sodium bicarbonate was acidified by adding
hydrochloric acid to a pH of about 2-4, and the oestrogens
extracted with ether. The oestrogen fraction was purified on
two column systems using DEAE Sephadex with acetic acid
buffer (0.05 M, pH 12)-methanol (75:25, w/w) as mobile
system and QAE Sephadex in the boric acid form using
methanol and acetic acid (0.05 M, pH 9-9.3) in methanol as
mobile phase (Fotsis and Adlercreutz, 1987). Oestriol (E3), E1
and E2 were separated by reverse-phase HPLC using Hypersil
ODS 5 gim (Chrompack) 4.6 x 250 mm column and a mobile
phase of acetonitrile/phosphate buffer 0.05 M, pH 3.
Because the amount of labelled E2 was much lower than
the amount of E1 and E3 excreted in the urine, we used the
mean value of the ratio between the amount of 3H-labelled
and '4C-labelled E, and 3H-labelled and 14C-labelled E3 to
calculate the ratio between 3H-labelled and '4C-labelled
oestrogens in the urine. Accordingly, we calculated the
percentage aromatisation from the equation:
[3H]Eur/[14C]Eur %_ aromatisation= [______________ x 100
[3H]Ainj/[14C]El inj
where [3H]Eur/['4C]Eur is the mean value of the ratio of 3H- to
'4C-labelled EB and E3 in the urine and [3H]Ainj and ["4C]E,inj
are the amounts of 3H-labelled A and '4C-labelled El injected
into the patient.
Plasma hormone measurements
Blood samples for E2, El, EBS and A measurements were
obtained between 08.00 and 10.00 after an overnight fast
before daily drug intake and before tracer injections on days
-3, 25 and 53. Blood was collected in sodium-heparinised
vials, and plasma separated by centrifugation and stored at
-20°C until analysis. Plasma levels of E2 and EB were
determined by methods reported elsewhere (Dowsett et al.,
1987; L0nning et al., 1995). The sensitivity limit for E2 and El
was 2.1 and 6.3 pmol 11 respectively. Plasma levels of EIS
were determined by a novel highly sensitive assay involving
purification and derivatisation into E2 and RIA analysis using
E2-6-carboxy-methyloxime-[2-'251]iodohistamine as tracer li-
gand (L0nning and Ekse, 1995). The sensitivity limit for EBS
using this method is 2.7 pmol 1-'. Plasma A was measured by
a commercial radioimmunoassay kit obtained from Diag-
nostic Systems Lab. (USA).
Measurement ofplasma levels of anastrozole
Plasma levels of anastrozole were measured in fasting blood
samples obtained before daily drug intake and before tracer
injection on days -3, 25 and 53. Venous blood was taken
into lithium-heparinised tubes, centrifuged, and the plasma
obtained stored at - 20'C until analysis. All samples from
each patient were analysed in the same batch. Anastrozole
was determined using a gas liquid chromatography method
with a sensitivity limit of 3.0 ng ml-'.
Statistical analysis
Percentage aromatisation and plasma hormone levels on
treatment with 1 and 10 mg of anastrozole were compared
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with pretreatment values by analysis of variance (ANOVA).
Previous studies from our group have revealed plasma
oestrogen levels in post-menopausal breast cancer patients
to be well fitted to a log-normal distribution (L0nning et al.,
1995). Accordingly, all values are expressed as geometric
means with 95% confidence intervals. The mean value of
percentage suppression from baseline for a parameter was
calculated as 100 minus X, where X is the geometric mean
value of the individual parameters in the on-treatment
situation expressed as percentage of pretreatment values.
Results
In vivo aromatase inhibition
Treatment with anastrozole 1 and 10 mg reduced in vivo
aromatisation from an initial value of 2.25% (95%
confidence interval 1.73% -2.92%) to 0.074% (0.064% -
0.083%) and 0.043% (0.021%-0.082%) respectively (Table
I). This corresponds to a mean suppression of 96.7% and
98.1% (P<0.005). Except for one patient (no. 9) who
experienced a suppression of in vivo aromatisation of only
78.2% during treatment with anastrozole 10 mg o.d., all
patients had in vivo aromatisation suppressed by >93.7%
during treatment with both doses of anastrozole.
Comparing the percentage aromatisation during treatment
with arimidex 1 and 10 mg, an arithmetic difference of 0.21%
(95% confidence interval -4.99 to 4.57%) was found.
However, if the analysis was repeated excluding the outlier
patient (no. 9), in vivo aromatisation was suppressed by
96.0% during treatment with 1 mg and 98.6% during
treatment with 10 mg, in which case the difference between
the two situations became statistically significant (P<0.01).
Calculating the ratio of the percentage aromatisation during
treatment with arimidex 10 mg compared with 1 mg, this
revealed a geometric mean value of 0.58 (95% confidence
interval 0.29- 1.15).
Table II Percentage suppression of plasma oestrogen levels during
treatment with anastrozole 1 and 10 mg
Oestrone Oestradiol Oestrone sulphate
Drug dose I mg 10 mg I mg 10 mg I mg 10 mg
Patient
2
3
4
S
6
7
8
9
10
11
12
Geom.a
95% 1.b
95% u.c
93.1*
77.1
77.7
92.8*
91.7*
89.6*
83.8
76.9
75.7
83.6
93.2
88.3
82.2
82.5
92.8*
91.7*
89.6*
82.0
80.2
79.4
75.7
93.4
86.6
62.6
79.4
93.5*
85.0*
83.1
89.5
74.1*
79.0*
71.8
93.5*
79.3
65.3
76.1
93.5*
85.0*
85.2*
93.4
74.1*
78.0
58.8
93.5*
95.6
58.4
93.0
96.4
92.4
94.8
91.0
92.9
96.0
89.6
98.1
97.1
61.8
82.8
99.5
96.3
97.4
96.7
97.2
97.4
90.9
94.9
86.8 86.5 84.0 83.5 93.5 95.7
81.0 81.6 76.5 74.1 89.0 90.7
90.7 90.1 89.1 89.5 96.1 98.0
Values<sensitivity limit of the method. Geometric mean value.
bLower limit ofthe 95% confidence interval ofthe mean.cUpper limit
ofthe 95% confidence interval ofthe mean.
N' N
\ -/ N
l
NC
CH3
L;H3 CN
Figure 1 Structure of anastrozole (Arimidex).
Plasma sex hormone levels
Many patients achieved plasma levels of E2 and E, during
treatment that were below the sensitivity limits of the assay,
in which case the value was given as the sensitivity limit
(Table II and Figure 2).
Mean plasma level of E, was suppressed from
73.0 pmol 1-1 to 9.7 pmol 1-' (mean suppression of 86.8%)
and 9.8 pmol I-' (mean suppression of 86.5%) during
treatment with anastrozole 1 mg and 10 mg respectively
(P<0.005). Plasma levels of E2 fell from a mean value of
17.7 pmol 1-' before treatment to 2.8 pmol 1-l and
Table I Effects of treatment with anastrozole 1 and 10 mg on
peripheral aromatisation
Pretreatment Anastrozole (I mg) Anastrozole (10 mg,
Patient Arom.%a Arom.%a Supp.%b Arom.%a Supp.%
3 3.06 0.074 97.6 0.028 99.1
4 1.99 0.085 95.7 0.021 98.9
5 1.79 0.064 96.4 0.023 98.7
6 4.72 0.067 98.6 0.066 98.6
7 1.77 0.068 96.1 0.033 98.1
8 2.85 0.080 97.2 0.025 99.1
9 1.94 0.061 96.8 0.422 78.2
10 1.46 0.058 96.1 0.023 98.5
11 1.60 0.100 93.7 0.082 94.9
12 2.83 0.091 96.8 0.034 98.8
Geom.c 2.25 0.074 96.7 0.043 98.1
95% .d 1.73 0.065 95.6 0.022 96.1
95% u. 2.92 0.084 97.5 0.083 99.1
aPercentage of aromatisation. bPercentage suppression from base-
line. cGeometrical mean value. dLower limit of the 95% confidence
interval ofthe mean. eUpperlimit ofthe 95% confidence interval ofthe
mean.
2.9 pmol 1-1 (mean suppression of 84.0% and 83.5%
respectively, P<0.005), and plasma levels of EIS decreased
from a mean value of 387.2 pmol l-1 to 25.3 pmol 1` and
16.9 pmol 1-' (mean suppression of 93.5% and 95.7%
respectively, P<0.005). No significant differences between
plasma levels of any of the oestrogens during treatment with
the two doses of anastrozole were seen.
Treatment with anastrozole had no significant influence on
plasma levels of A (mean level of A before and during
treatment with anastrozole 1 and 10 mg o.d. 4.1 nmol I-',
3.3 nmol 1` and 3.1 nmol `l respectively).
Plasma levels of anastrozole
The mean plasma level of anastrozole was 37.7 ng ml-'
(range 22.0-83.9 ng ml-1) during treatment with a drug
dose of 1 mg and 341.4 ng ml-1 (range 160.0-644.0 ng ml-')
during treatment with a dose of 10 mg daily.
Discussion
Despite the fact that aminoglutethimide has been in clinical
use for two decades and several other aromatase inhibitors
for 5-10 years, many questions related to their biochemical
action remain unaddressed. While the first study evaluating in
vivo aromatase inhibition during treatment with aminoglu-
tethimide reported the drug to inhibit the conversion of A to
E1 by about 98% (Santen et al., 1978) and contemporary
studies by us (MacNeill et al., 1992; Jones et al., 1992;
L0nning et al., 1991) and others (Reed et al., 1990) have
found aminoglutethimide, as well as novel aromatase
inhibitors such as formestane and fadrozole, to inhibit in
vivo aromatisation by about 90%, plasma oestrogens have
been found to be sustained at 30-50% of their control levelsa
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Figure 2 Plasma levels of oestrone (a), oestradiol (b) and
oestrone sulphate (c) in individual patients before treatment and
following 4 weeks of treatment with anastrozole 1 mg and 1Omg.
Dashed line gives the sensitivity limit of the assays.
in patients treated with these drugs (Santen et al., 1982b;
Vermeulen et al., 1983; Dowsett et al., 1989,1990). Recent
studies found the triazole drugs letrozole and vorozole to
inhibit in vivo aromatisation by a mean of 98.5% and 93%
respectively (Dowsett et al., 1995; Wall et al., 1993). While
one group found letrozole to suppress plasma and urinary
oestrogens by 90-95% (Masamura et al., 1994; Demers et
al., 1993), others reported vorozole and letrozole to suppress
plasma oestrogens by 55-90% (Iveson et al., 1993; Johnston
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et al., 1994), again revealing an internal inconsistency
between the degree of aromatase inhibition and percentage
of plasma oestrogen suppression. Such a difference could be
due either to alternative (non-aromatase-dependent) oestro-
gen sources or lack of sensitivity of the radioimmunoassays
used for plasma oestrogen measurement. Thus, there is a
need to compare in vivo aromatase inhibition and plasma
oestrogen suppression to develop the concept of aromatase
inhibition in breast cancer treatment further.
This study was designed to determine in vivo aromatase
inhibition and plasma oestrogen suppression during treat-
ment with anastrozole, a novel aromatase inhibitor. Animal
investigations (Plourde et al., 1995) suggest this drug to be a
highly potent aromatase inhibitor, and preliminary studies in
post-menopausal healthy women and breast cancer patients
suggest the drug to be effective in suppressing plasma levels
of E2 (Plourde et al., 1994). To determine in vivo
aromatisation, we used a sensitive and specific HPLC assay
previously used by our group to evaluate different aromatase
inhibitors (Jacobs et al., 1991). Plasma levels of E2 and E,
were measured with sensitive methods previously validated in
our laboratories (Dowsett et al., 1987; L0nning et al., 1995).
However, owing to low levels of these oestrogens (mean
concentration of plasma E2 and E, of about 20 and
75 pmol 1-') in post-menopausal women (L0nning et al.,
1995), it remains difficult to detect>90% suppression ofthese
oestrogens from pretreatment levels. On the other hand, the
oestrogen conjugate E,S is found in much higher concentra-
tions than E2 and E, in post-menopausal women. Plasma E2,
El and E,S are at equilibrium (L0nning et al., 1990). Thus, as
long as an aromatase inhibitor does not influence enzymes
involved in the interconversion of these oestrogens
(sulphatase or sulphotransferase) or interacts with oestrogen
metabolism (L0nning and Kvinnsland, 1988), plasma E,S and
the unconjugated oestrogens should be expected to be
suppressed by the same percentage during treatment with
aromatase inhibitors. To measure E,S, we used a highly
sensitive assay recently developed to determine plasma levels
of this oestrogen in the very low range (L0nning and Ekse,
1995). Assuming a mean concentration of plasma E,S of
about 400 pmol 1' in post-menopausal women, with a
sensitivity of 2.7 pmol 1' this assay should be able to detect
a 98-99% suppression of this plasma oestrogen conjugate.
This study reveals two important findings. First, it shows
anastrozole, given as 1 mg or 10 mg o.d., to inhibit in vivo
aromatisation by a mean value of 96.7% and 98.1%,
respectively, and so to be one of the most potent aromatase
inhibitors investigated so far. Secondly, treatment with
anastrozole 1 and 10 mg o.d. suppressed plasma E,S by a
mean value of 93.5% and 95.7% respectively. Therefore, our
results revealed anastrozole at both doses administered to
suppress plasma levels of E,S by a percentage close to the
percentage aromatase inhibition. Of note, although without
statistical significance, eight out of ten patients experienced a
greater degree of E,S suppression when the higher dose of
anastrozole was given. While we did not see a similar
suppression of plasma EB and E2, it is notable that many
patients achieved plasma values of these oestrogens that were
below the sensitivity limit of the methods. Thus, it is likely
that we underestimated the percentage suppression of plasma
E, and E2. These data indicate that with the application of
sufficiently sensitive assays, oestrogen suppression and
aromatase inhibition are closely parallel in post-menopausal
women.
While all patients experienced a suppression of in vivo
aromatisation by >93.7% during treatment with anastrozole
>1 mg o.d., one patient experienced an inhibition of 78.2%
only during treatment with 10 mg o.d. No definite
explanation for this observation was found. It is noteworthy
that this patient was the one experiencing the lowest plasma
concentration of anastrozole (160 ng ml-') when treated with
a dose of 10 mg daily, but this concentration was
considerably higher than the highest plasma concentration
observed among our patients when they were treated with aAim-nias bddbUs.wf ----hm7m
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drug dose of 1 mg daily. All medication received in this trial
was accounted for, and it is not likely that the patient may
have failed to take her medication as prescribed.
The difference in aromatase inhibition between anastrozole
given as 1 and 10 mg o.d. (arithmetic difference of 0.21%,
difference of 1.4% between geometrical mean values) was not
of statistical significnce. However, eight out of ten patients
achieved a better aromatase inhibition during treatment with
the 10 mg dose compared with I mg. Excluding the one
outlier patient (no. 9) from the analysis revealed a difference
in aromatisation of statistical signifi. Thus, there is
evidence that most patients may achieve a somewhat better
aromatase inhibition on 10 mg compared with I mg of
anastrozole. However, the small magnitude of this difference
and the fact that it was not accompanied by any significant
difference in plasma oestrogen levels suggest that this
difference may be of little clinical importance. Thus, our
results and previous observations by others (Yates et al.,
1992), evaluating plasma El and E2 suppression with
anastrozole single doses up to 60 mg, suggest that a dose
escalation above 1 mg anastrozole once daily may not
enhance plasma oestrogen suppression any further.
In conclusion, this study showed anastrozole given as 1 mg
or 10 mg o.d. to be highly potent in inhibiting in vivo
aromatisation and suppressing plasma oestrogens in post-
menopausal breast cancer patients. Our results revealed
anastrozole to suppress plasma levels of E,S by a percentage
approaching the percentage aromatase inhibition, providing
an internal consistency between alterations in the in vivo
aromatisation and plasma oestrogen levels in these patients.
The findings support the concept that effective aromatase
inhibition is accompanied by a profound suppression of
plasma oestrogens in post-menopausal breast cancer patients
and refute a hypothesis of alternative sources of plasma
oestrogens in such patients.
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